Notice: This company has been marked as potentially delisted and may not be actively trading. Millendo Therapeutics (MLND) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends MLND vs. OCUP, BYSI, LPTX, CTMX, IMRX, SPRO, ALXO, CELU, INCR, and CLRBShould you be buying Millendo Therapeutics stock or one of its competitors? The main competitors of Millendo Therapeutics include Ocuphire Pharma (OCUP), BeyondSpring (BYSI), Leap Therapeutics (LPTX), CytomX Therapeutics (CTMX), Immuneering (IMRX), Spero Therapeutics (SPRO), ALX Oncology (ALXO), Celularity (CELU), InterCure (INCR), and Cellectar Biosciences (CLRB). These companies are all part of the "medical" sector. Millendo Therapeutics vs. Ocuphire Pharma BeyondSpring Leap Therapeutics CytomX Therapeutics Immuneering Spero Therapeutics ALX Oncology Celularity InterCure Cellectar Biosciences Ocuphire Pharma (NASDAQ:OCUP) and Millendo Therapeutics (NASDAQ:MLND) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, community ranking, analyst recommendations and earnings. Which has more risk & volatility, OCUP or MLND? Ocuphire Pharma has a beta of 0.2, indicating that its share price is 80% less volatile than the S&P 500. Comparatively, Millendo Therapeutics has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500. Do institutionals and insiders believe in OCUP or MLND? 15.0% of Ocuphire Pharma shares are held by institutional investors. 8.7% of Ocuphire Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the media prefer OCUP or MLND? In the previous week, Ocuphire Pharma had 1 more articles in the media than Millendo Therapeutics. MarketBeat recorded 1 mentions for Ocuphire Pharma and 0 mentions for Millendo Therapeutics. Ocuphire Pharma's average media sentiment score of 0.00 equaled Millendo Therapeutics'average media sentiment score. Company Overall Sentiment Ocuphire Pharma Neutral Millendo Therapeutics Neutral Does the MarketBeat Community favor OCUP or MLND? Ocuphire Pharma received 37 more outperform votes than Millendo Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformOcuphire PharmaOutperform Votes3769.81% Underperform Votes1630.19% Millendo TherapeuticsN/AN/A Which has better earnings & valuation, OCUP or MLND? Ocuphire Pharma has higher revenue and earnings than Millendo Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOcuphire Pharma$16.45M0.00-$9.99M-$0.49N/AMillendo TherapeuticsN/AN/A-$36.41MN/AN/A Do analysts prefer OCUP or MLND? Ocuphire Pharma presently has a consensus target price of $16.00, suggesting a potential upside of 0.00%. Given Ocuphire Pharma's stronger consensus rating and higher probable upside, research analysts plainly believe Ocuphire Pharma is more favorable than Millendo Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ocuphire Pharma 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Millendo Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is OCUP or MLND more profitable? Millendo Therapeutics has a net margin of 0.00% compared to Ocuphire Pharma's net margin of -85.75%. Ocuphire Pharma's return on equity of -30.19% beat Millendo Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Ocuphire Pharma-85.75% -30.19% -27.55% Millendo Therapeutics N/A -91.03%-72.44% SummaryOcuphire Pharma beats Millendo Therapeutics on 12 of the 14 factors compared between the two stocks. Ad Crypto 101 MediaBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW Get Millendo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLND and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MLND vs. The Competition Export to ExcelMetricMillendo TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$17.11M$6.48B$5.07B$8.80BDividend YieldN/A8.11%4.99%4.07%P/E RatioN/A4.9789.5613.60Price / SalesN/A371.451,224.8087.40Price / CashN/A52.5939.4536.27Price / Book0.5010.306.976.33Net Income-$36.41M$153.61M$119.04M$225.93M Millendo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MLNDMillendo TherapeuticsN/A$0.90+3.5%N/A-77.1%$17.11MN/A0.0012Gap UpOCUPOcuphire Pharma0.922 of 5 starsN/A$16.00+∞N/A$30.33M$16.45M-2.3914High Trading VolumeBYSIBeyondSpringN/A$1.71-0.6%N/A+86.1%$66.74M$1.75M0.0080LPTXLeap Therapeutics2.3936 of 5 stars$2.60+0.4%$7.50+188.5%+25.1%$66.56M$1.50M0.0040Positive NewsCTMXCytomX Therapeutics4.3829 of 5 stars$0.85-2.8%$5.77+582.4%-37.4%$66.20M$101.21M5.12170Short Interest ↓IMRXImmuneering2.8292 of 5 stars$2.10+2.9%$12.80+509.5%-63.4%$65.21M$320,000.000.0060Analyst ForecastSPROSpero Therapeutics4.5933 of 5 stars$1.19-0.7%$5.00+319.5%-2.4%$64.99M$103.78M17.1546Analyst ForecastALXOALX Oncology3.3343 of 5 stars$1.22+0.8%$12.50+924.6%-87.7%$64.34MN/A0.0040CELUCelularity0.5369 of 5 stars$2.91-1.0%N/A+42.7%$63.99M$22.77M0.00220News CoverageINCRInterCure1.2529 of 5 stars$1.36+1.9%N/A+16.0%$61.93M$96.61M0.00350Positive NewsCLRBCellectar Biosciences2.4949 of 5 stars$1.49-4.8%$20.00+1,246.8%-27.8%$61.29MN/A-0.9110Analyst ForecastShort Interest ↓Analyst RevisionNews Coverage Related Companies and Tools Related Companies OCUP Alternatives BYSI Alternatives LPTX Alternatives CTMX Alternatives IMRX Alternatives SPRO Alternatives ALXO Alternatives CELU Alternatives INCR Alternatives CLRB Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MLND) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Millendo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Millendo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MLND Stock Alerts